冲刺300亿!独家注射剂暴涨1825%,海正、方盛上榜,恒瑞、石药猛攻1类新药

米内网
Nov 17, 2025

精彩内容近日,重庆药友制药的瑞舒伐他汀钙片、北京福元医药的依折麦布阿托伐他汀钙片(Ⅰ)获批生产并视同过评。米内网数据显示,近年来中国三大终端六大市场血脂调节剂(化+生+中)销售额呈逐年递增态势,2024年接近280亿元,2025年朝着300亿的关口迈进;化学药占主导地位,TOP20品牌洗牌,超10亿大品种承压;生物药涨势迅猛,独家注射剂暴涨1825%;中成药表现亦不俗,独家品种霸榜。近年来中国三大...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10